A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
Phase 2
Active, not recruiting
NCT05246514
| Condition | HER2-mutant Non-Small Cell Lung Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | AstraZeneca |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 72 participants |
|---|
| Interventions | Trastuzumab deruxtecan |
|---|
| Start date | Jul 13, 2022 |
|---|
| Completion date | Nov 4, 2024 |
|---|
| Results posted | Dec 4, 2024 |
|---|
Summary
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
ICR-assessed ORR (Objective Response Rate)
Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off) · Percentage of participants
| T-DXd Arm | 56.9 Percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.